Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Vancocin Gets Cmte. Endorsement, But So Do New Brand Products

Executive Summary

When the Pharmaceutical Science and Clinical Pharmacology Advisory Committee endorsed dissolution data for establishing bioequivalence of generic versions of Vancocin, it not only paved the way for generic applicants, but it also highlighted the need for additional, more accommodating forms of the drug

You may also be interested in...



FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions

46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.

FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions

46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.

Vancocin Generics Launch As FDA Finds ViroPharma’s Label Fails “Significant New Use” Test

FDA delivers an 87-page chef d'oeuvre that concludes the ViroPharma’s long-running battle to block ANDA approvals. In the citizen petition response, FDA rejects the firm’s scientific and legal arguments and concludes the antibiotic is not eligible for three years of Hatch-Waxman marketing exclusivity under a 2008 law. Although ViroPharma says it plans to sue FDA, the company may have bigger problems on its hands with an FTC investigation.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel